An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Part of paid clinical trials in Costa Mesa, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03994601
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986288 — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days
  • Regorafenib — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

Key Dates

Start date
Sep 6, 2019
Status verified
Dec 2025
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024

Study Design

Enrollment
219 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: BMS-986288 Monotherapy
  • Experimental: Arm B: BMS-986288 in combination with Nivolumab
  • Experimental: Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib

Primary Outcome Measure

Safety Related Events for Cohorts 1A, 1B and 2B. [ Time Frame: approximately 6 months ]

Locations (6)

FacilityCityStateZIPSite coordinators
Local Institution - 0075Costa MesaCalifornia92627-
Local Institution - 0050OrangeCalifornia92868-3201-
Local Institution - 0005AuroraColorado80045-
Local Institution - 0002BaltimoreMaryland21287-
Local Institution - 0004St LouisMissouri63110-
Local Institution - 0001HackensackNew Jersey07601-

Related coverage on Hipa.ai

Find similar trials in Costa Mesa, CA

By research site
Local Institution - 0075· Costa Mesa, CALocal Institution - 0050· Orange, CALocal Institution - 0005· Aurora, COLocal Institution - 0002· Baltimore, MDLocal Institution - 0004· St Louis, MOLocal Institution - 0001· Hackensack, NJ

Related Studies